Among adults with incident type 2 diabetes, utilization of GLP‐1 receptor agonists and SGLT‐2 inhibitors increased in parallel with evolving guidelines that prioritized the management of CVD and CKD comorbidities. This evidence concerns the gene GLP1R and chronic kidney disease.